Oral Dryness and Medication Burden in Older Adults: A Comprehensive Review

Abstract

Oral dryness, or xerostomia, is a prevalent and clinically significant issue among older adults, particularly those with polypharmacy. This review synthesizes current evidence regarding the epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic criteria, and management strategies for oral dryness in the context of medication burden, providing practical guidance for healthcare professionals. Recent advances and guideline-based recommendations are discussed to inform best practices in geriatric oral care.

Introduction

Oral dryness, commonly referred to as xerostomia, poses substantial health challenges in older adults. Age-related physiological changes, comorbidities, and polypharmacy collectively increase susceptibility to this condition. Oral dryness adversely affects speech, mastication, swallowing, taste, oral hygiene, and overall quality of life. Its etiological complexity, especially in the presence of multiple medications, underscores the need for a multidimensional clinical approach. This review evaluates the current understanding of oral dryness in older adults, emphasizing the impact of medication burden and integrating recent scientific evidence to guide clinical decision-making.

Epidemiology / Disease Burden

Epidemiological studies indicate a high prevalence of xerostomia among older adults, with estimates ranging from 20% to 40% in community-dwelling elders and up to 80% in institutionalized populations. The aging global demographic has amplified the clinical significance of oral dryness, making it a priority in geriatric care. Polypharmacy, defined as the use of five or more medications, is reported in over 50% of adults aged 65 and above, further increasing xerostomia risk. The condition leads to significant morbidity, including increased dental caries, oral infections, dysphagia, nutritional deficits, and diminished psychosocial well-being. Studies demonstrate a direct association between medication count and xerostomia severity, making medication review an essential component of geriatric assessment.

Pathophysiology

Saliva production is regulated by a complex interplay of neural, hormonal, and local factors. In older adults, age-related atrophy of salivary glands, diminished acinar cell function, and reduced neural stimulation contribute to decreased salivary flow. Medications exacerbate this decline through anticholinergic, sympathomimetic, and diuretic effects. Common drug classes implicated include antidepressants, antihypertensives, antipsychotics, antihistamines, and opioids. These agents reduce parasympathetic tone or directly inhibit salivary gland secretion. Furthermore, comorbid conditions such as diabetes mellitus, Sjögren’s syndrome, and Parkinson’s disease may contribute to or exacerbate oral dryness, creating a multifactorial pathophysiological milieu in geriatric patients.

Risk Factors

Major risk factors for oral dryness in older adults include advanced age, female sex, polypharmacy, and the presence of chronic diseases. Polypharmacy is the most modifiable risk factor, with the cumulative anticholinergic burden being a critical determinant. Additional contributors include radiation therapy to the head and neck, systemic dehydration, and lifestyle factors such as smoking and excessive caffeine intake. Recognizing these risk factors enables targeted prevention and early intervention strategies in vulnerable populations.

Clinical Features

Oral dryness manifests as subjective dryness, burning sensation, altered taste, difficulty in chewing and swallowing, and increased thirst. Examination may reveal dry, fissured oral mucosa, atrophic tongue, sticky saliva, angular cheilitis, and an increased incidence of dental caries and oral candidiasis. The clinical impact extends beyond the oral cavity, affecting nutritional intake, speech, and overall health status. Early recognition of these features is crucial for prompt diagnosis and management.

Diagnosis

Diagnosis of xerostomia is primarily clinical, based on patient-reported symptoms and physical examination. Objective assessment includes measurement of unstimulated and stimulated salivary flow rates, with values below 0.1 mL/min (unstimulated) and 0.7 mL/min (stimulated) indicating hyposalivation. The use of validated questionnaires, such as the Xerostomia Inventory, can aid in symptom quantification. Salivary gland imaging and sialometry may be indicated in complex cases or when underlying pathology is suspected. Comprehensive medication review is essential to identify offending agents.

Treatment & Management

Management of oral dryness in older adults necessitates a multifactorial approach. The cornerstone is medication review and rationalization, aiming to minimize anticholinergic burden and avoid unnecessary polypharmacy. Non-pharmacological interventions include patient education, frequent sips of water, sugar-free chewing gum, and maintenance of optimal oral hygiene. Artificial saliva substitutes and oral moisturizing agents provide symptomatic relief. Pharmacological therapies, such as pilocarpine and cevimeline, may be considered in selected cases with residual gland function but require cautious use in the elderly due to potential side effects. Interdisciplinary care, involving geriatricians, pharmacists, and dental professionals, is recommended for comprehensive management.

Recent Advances / Emerging Therapies

Recent advances in the management of oral dryness include the development of novel saliva stimulants, targeted therapies for underlying autoimmune conditions, and advancements in drug formulation to reduce xerogenic potential. Low-level laser therapy and acupuncture have shown promise in pilot studies but require further validation. Digital health tools and telemedicine platforms are emerging to facilitate remote symptom monitoring and patient education. The ongoing research into salivary gland tissue engineering and regenerative therapies may offer future prospects for restoring glandular function in severe cases.

Guideline Recommendations

Current clinical guidelines emphasize regular medication review, identification, and minimization of xerogenic drugs. The American Geriatrics Society recommends periodic assessment of oral health and salivary function in older adults, particularly those with polypharmacy. European and national guidelines advocate for interdisciplinary management, patient-centered care, and prompt referral to oral health specialists in persistent cases. Evidence-based recommendations support the use of non-pharmacological interventions as first-line therapy, with pharmacological agents reserved for refractory symptoms and after thorough risk-benefit assessment.

Conclusion

Oral dryness in older adults, intricately linked to medication burden, remains a prevalent and under-recognized clinical challenge. An evidence-based, multidisciplinary approach encompassing medication optimization, non-pharmacological interventions, and tailored pharmacotherapy can significantly improve patient outcomes. Ongoing research and adherence to guideline recommendations are essential to advancing care quality and reducing the burden of xerostomia in the aging population.